BioLife Solutions, Inc. reported preliminary revenue of $24.8 million for its fourth quarter of 2025, a 20 % increase from the $20.7 million earned in the same period a year earlier. The figure also beat the consensus estimate of $24.1 million, a $0.7 million lift that reflects stronger demand for the company’s core biopreservation products and a favorable mix shift toward higher‑margin items.
Full‑year 2025 revenue reached $96.2 million, up 29 % from $74.6 million in 2024 and exceeding the high end of the company’s raised guidance range of $95.0 million to $96.0 million. The guidance beat was driven by a 28 % adjusted EBITDA margin in Q3 2025, up from 24 % in Q2, indicating that operating leverage is translating into higher profitability as the company scales its recurring‑revenue portfolio.
Management highlighted the divestiture of the evo cold‑chain subsidiary in October 2025, which closed for $25.5 million in cash. The sale removed a legacy, low‑margin business and positioned BioLife as a pure‑play cell‑processing company focused on high‑margin, recurring revenue franchises. CEO Roderick de Greef said the divestiture “has positioned us as a pure‑play cell‑processing company focused on high‑value, recurring revenue franchises,” underscoring the strategic shift toward a more profitable model.
The biopreservation segment, the primary growth driver, generated $28.1 million in Q3 2025 and contributed 20 % of total revenue. The segment’s expansion is fueled by increased adoption in commercial cell and gene therapies, new product introductions, and market share gains in the U.S. and Europe. The 28 % adjusted EBITDA margin in Q3 reflects the high‑margin nature of these products and the company’s ability to maintain pricing power amid a competitive landscape.
Analysts polled by FactSet had expected Q4 revenue of $24.1 million; BioLife’s $24.8 million beat was viewed as a sign of strong execution. The company’s guidance for 2026, to be released in February, is expected to build on the momentum, with management projecting continued revenue growth and further margin expansion as operating leverage improves.
Management reiterated confidence in the company’s trajectory, noting that the “streamlined, market‑leading product portfolio and strong financial position support our expectations for profitable growth and long‑term value creation.” The outlook signals a continued focus on high‑margin, recurring revenue franchises and a belief that the company’s strategic repositioning will sustain growth in the coming years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.